Freeline to Present on Its Fabry and Gaucher Disease AAV-Based Gene Therapies at the 18th Annual WORLDSymposium™
27. Januar 2022 16:01 ET
|
Freeline Therapeutics
LONDON, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06. Januar 2022 16:01 ET
|
Freeline Therapeutics
LONDON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline Announces FDA Clearance of Investigational New Drug Application for FLT201 for Gaucher Disease Type 1
06. Januar 2022 07:00 ET
|
Freeline Therapeutics
FLT201 is the first AAV gene therapy program to enter the clinic for Gaucher disease Type 1 FLT201 Phase 1/2 trial for Gaucher disease Type 1 on track for patient dosing in the first half of 2022 ...
Freeline To Participate In Conferences During January 2022
04. Januar 2022 16:01 ET
|
Freeline Therapeutics
LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the "Company" or "Freeline"), a clinical-stage biotechnology company developing transformative...
Freeline Announces 2022 Corporate Priorities and Guidance
13. Dezember 2021 17:40 ET
|
Freeline Therapeutics
Promising execution in the clinic with programs in hemophilia B, Fabry disease and Gaucher disease; potential to deliver transformative therapies driven by Freeline’s differentiated platform Data...
Freeline Presents Long-Term Follow-Up Data from Phase 1/2 B-AMAZE Trial in Hemophilia B at the 2021 ASH Annual Meeting and Announces Early Initiation of Phase 1/2 B-LIEVE Dose-Confirmation Trial
13. Dezember 2021 09:01 ET
|
Freeline Therapeutics
B-AMAZE long-term follow up data demonstrate sustained FIX expression up to 3.5 years; potential for expression levels in the normal range with relatively low vector doses B-LIEVE trial to...
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06. Dezember 2021 16:01 ET
|
Freeline Therapeutics
LONDON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline to Participate in Evercore ISI 4th Annual HealthCONx Conference
23. November 2021 16:01 ET
|
Freeline Therapeutics
LONDON, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline to Participate in Stifel 2021 Virtual Healthcare Conference
10. November 2021 16:01 ET
|
Freeline Therapeutics
LONDON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative...
Freeline Reports New Data from Fabry Disease Program, Pipeline and Company Updates, Including Appointment of Pamela Foulds, MD as Chief Medical Officer, and Third Quarter 2021 Financial Results
09. November 2021 16:01 ET
|
Freeline Therapeutics
Lowest dose cohort of MARVEL-1 trial of FLT190 for Fabry disease demonstrates durable α-Gal A expression over two years in the first patient and promising efficacy with near normal α-Gal A levels in...